ANDA 205447, held by Breckenridge Pharmaceutical. Bendamustine Hydrochloride.
As of Nov 21, 2026, ANDA 205447 (Bendamustine Hydrochloride), held by Breckenridge Pharmaceutical, was first approved by FDA on Feb 14, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 14, 2023 | Original application | Approved | None posted |
| Bendamustine Hydrochloride25MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Discontinued |
| Bendamustine Hydrochloride100MG/VIAL · powder;intravenous | Bendamustine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters